1. Home
  2. ALDX vs JHS Comparison

ALDX vs JHS Comparison

Compare ALDX & JHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALDX
  • JHS
  • Stock Information
  • Founded
  • ALDX 2004
  • JHS 1973
  • Country
  • ALDX United States
  • JHS United States
  • Employees
  • ALDX N/A
  • JHS N/A
  • Industry
  • ALDX Biotechnology: Pharmaceutical Preparations
  • JHS Finance Companies
  • Sector
  • ALDX Health Care
  • JHS Finance
  • Exchange
  • ALDX Nasdaq
  • JHS Nasdaq
  • Market Cap
  • ALDX 160.8M
  • JHS 131.4M
  • IPO Year
  • ALDX 2014
  • JHS N/A
  • Fundamental
  • Price
  • ALDX $3.05
  • JHS $11.06
  • Analyst Decision
  • ALDX Strong Buy
  • JHS
  • Analyst Count
  • ALDX 2
  • JHS 0
  • Target Price
  • ALDX $9.50
  • JHS N/A
  • AVG Volume (30 Days)
  • ALDX 769.8K
  • JHS 32.8K
  • Earning Date
  • ALDX 07-31-2025
  • JHS 01-01-0001
  • Dividend Yield
  • ALDX N/A
  • JHS 3.96%
  • EPS Growth
  • ALDX N/A
  • JHS N/A
  • EPS
  • ALDX N/A
  • JHS 0.02
  • Revenue
  • ALDX N/A
  • JHS N/A
  • Revenue This Year
  • ALDX N/A
  • JHS N/A
  • Revenue Next Year
  • ALDX N/A
  • JHS N/A
  • P/E Ratio
  • ALDX N/A
  • JHS $553.50
  • Revenue Growth
  • ALDX N/A
  • JHS N/A
  • 52 Week Low
  • ALDX $1.14
  • JHS $9.76
  • 52 Week High
  • ALDX $7.20
  • JHS $11.25
  • Technical
  • Relative Strength Index (RSI)
  • ALDX 61.89
  • JHS 40.79
  • Support Level
  • ALDX $2.60
  • JHS $11.03
  • Resistance Level
  • ALDX $3.24
  • JHS $11.14
  • Average True Range (ATR)
  • ALDX 0.22
  • JHS 0.09
  • MACD
  • ALDX 0.09
  • JHS -0.01
  • Stochastic Oscillator
  • ALDX 80.93
  • JHS 9.38

About ALDX Aldeyra Therapeutics Inc.

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.

About JHS John Hancock Income Securities Trust

John Hancock Income Securities Trust is a United States-based closed-ended diversified management investment company. Its primary objective is to generate a high level of current income consistent with prudent investment risk. The fund invests its net assets (plus borrowings for investment purposes) in income securities, consisting of marketable corporate debt securities, governmental obligations, and cash and commercial paper. A majority of its net assets are invested in debt securities that are rated, at the time of acquisition, investment-grade or in unrated securities determined by the Fund's investment advisor or subadvisor to be of comparable credit quality.

Share on Social Networks: